# OnCo record lm-299 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lm-299/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lm-299" ;
  schema:name "LM-299"@en ;
  schema:alternateName "MK-2010"@en ;
  schema:description "LM-299 is an experimental antibody that blocks two things at once: PD-1, a brake on the immune system, and VEGF, which feeds tumour blood vessels. LaNova Medicines discovered it and Merck licensed it in 2024, where it is called MK-2010."@en ;
  schema:url <https://onco.cc/drugs/lm-299/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/>, <https://clinicaltrials.gov/study/NCT06650566>, <https://clinicaltrials.gov/study/NCT07793942>, <https://clinicaltrials.gov/study/NCT07785609> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Bispecific antibody (PD-1 x VEGF)" ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/lanova-medicines/>, <https://onco.cc/companies/merck/> ;
  onco:trials <https://onco.cc/trials/nct06650566/> .